Remove Allergies Remove Immune Response Remove Medicine Remove Radiology
article thumbnail

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The lead Principal Investigator for the INNOVATE trial is Dr. Pablo Tebas , Professor of Medicine at the Hospital of the University of Pennsylvania. .

DNA 40
article thumbnail

Low-dose radiotherapy combined with immunotherapy eradicates metastatic cancer in mice

Bioengineer

“We’re excited–with such low doses of radiation, we didn’t expect the response to be so positive,” said lead author Ravi Patel, M.D., professor of radiology at the University of Wisconsin School of Medicine and Public Health, in collaboration with co-author Reinier Hernandez, Ph.D.,

article thumbnail

COVID-19 Pandemic Coverage

XTalks

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. China’s COVID-19 Vaccine: Sinovac Biotech and CanSino Biologics.